All In Biotech

Drug Trial Radar · NCT05316155

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants With Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

235

Actual

Start

Apr 11, 2022

Primary completion

Mar 30, 2028

Study completion Jul 24, 2029

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Apr 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) and evaluate preliminary clinical efficacy. Part 3 (dose expansion) will confirm safety and preliminary clinical activity at the RP2D. Part 4 (RP2D expansion; MoonRISe-2) will assess the overall complete response (CR) in participants with intermediate-risk-non-muscle invasive bladder cancer (IR-NMIBC; means the cancer cells are only in the bladder's inner lining).

Conditions

  • Non-Muscle Invasive Bladder Neoplasms

Interventions

  • Erdafitinib Intravesical Delivery SystemDrug

    Erdafitinib intravesical delivery system will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts 1 to 3: Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 7 years 4 months
  2. Parts 1 to 3: Number of Participants with AEs by SeverityTime frame: Up to approximately 7 years 4 months
  3. Part 1: Number of Participants with Dose-limiting Toxicity (DLT)Time frame: Up to 28 days
  4. Part 4: Overall Complete Response (CR) in Participants with Intermediate Risk-Non-Muscle Invasive Bladder Cancer (IR-NMIBC)Time frame: Up to approximately 7 years 4 months

Locations

59 sites in 8 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham - The Kirklin Clinic

    Birmingham, Alabama

  • University of Southern California

    Los Angeles, California

  • Urology Associates of Denver

    Lone Tree, Colorado

  • Urological Research Network

    Hialeah, Florida

  • Advanced Urology Institute

    Largo, Florida

  • Advent Health Orlando

    Orlando, Florida

  • Advanced Urology Institute 1

    Oxford, Florida

  • H Lee Moffitt Cancer Center

    Tampa, Florida

  • Northwestern University

    Chicago, Illinois

  • Associated Urological Specialists

    Chicago Ridge, Illinois

  • Urology of Indiana

    Greenwood, Indiana

  • Urologic Specialists of Northwest Indiana

    Merrillville, Indiana

  • University of Kentucky

    Lexington, Kentucky

  • Southern Urology LLC

    Lafayette, Louisiana

  • Greater Boston Urology

    Plymouth, Massachusetts

  • Specialty Clinical Research of St Louis

    St Louis, Missouri

  • Hackensack University Medical Center Urology

    Hackensack, New Jersey

  • Associated Medical Professionals

    Syracuse, New York

  • Levine Cancer Institute, Carolinas HealthCare System

    Charlotte, North Carolina

  • Central Ohio Urology Group

    Gahanna, Ohio

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

  • Low Country Urology Clinics

    North Charleston, South Carolina

  • Urology Associates

    Nashville, Tennessee

  • Urology Austin

    Austin, Texas

  • Urology San Antonio Research

    San Antonio, Texas

  • Vancouver Prostate Centre Diamond Health Care Centre

    Vancouver, British Columbia, Canada

  • Nova Scotia Health Authority

    Halifax, Nova Scotia, Canada

  • St Josephs Healthcare Hamilton

    Hamilton, Ontario, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • Universitatsklinikum Carl Gustav Carus Dresden

    Dresden, Germany

  • Urologicum Duisburg

    Duisburg, Germany

  • Universitatsklinikum Frankfurt

    Frankfurt am Main, Germany

  • Marien hospital Herne

    Herne, Germany

  • Urologie Neandertal Praxis Mettmann

    Mettmann, Germany

  • Universitatsklinikum Munster

    Münster, Germany

  • Universitaetsklinikum Ulm

    Ulm, Germany

  • Rambam Medical Center

    Haifa, Israel

  • Carmel Medical Center

    Haifa, Israel

  • Rabin Medical Center

    Petah Tikva, Israel

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.